These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
947 related articles for article (PubMed ID: 26934227)
21. Apoptosis and non-alcoholic fatty liver diseases. Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872 [TBL] [Abstract][Full Text] [Related]
22. Autophagy, NAFLD and NAFLD-Related HCC. Wu WKK; Zhang L; Chan MTV Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211 [TBL] [Abstract][Full Text] [Related]
23. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Behary J; Amorim N; Jiang XT; Raposo A; Gong L; McGovern E; Ibrahim R; Chu F; Stephens C; Jebeili H; Fragomeli V; Koay YC; Jackson M; O'Sullivan J; Weltman M; McCaughan G; El-Omar E; Zekry A Nat Commun; 2021 Jan; 12(1):187. PubMed ID: 33420074 [TBL] [Abstract][Full Text] [Related]
24. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852 [TBL] [Abstract][Full Text] [Related]
25. B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD). Bruzzì S; Sutti S; Giudici G; Burlone ME; Ramavath NN; Toscani A; Bozzola C; Schneider P; Morello E; Parola M; Pirisi M; Albano E Free Radic Biol Med; 2018 Aug; 124():249-259. PubMed ID: 29920340 [TBL] [Abstract][Full Text] [Related]
26. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291 [TBL] [Abstract][Full Text] [Related]
27. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231 [TBL] [Abstract][Full Text] [Related]
28. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease. Akie TE; Liu L; Nam M; Lei S; Cooper MP PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096 [TBL] [Abstract][Full Text] [Related]
29. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349 [TBL] [Abstract][Full Text] [Related]
30. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Bhowmick S; Singh V; Jash S; Lal M; Sinha Roy S Mitochondrion; 2021 May; 58():24-37. PubMed ID: 33581332 [TBL] [Abstract][Full Text] [Related]
31. Getting the Skinny on CD4(+) T Cell Survival in Fatty Livers. Walker CM; Lemon SM Immunity; 2016 Apr; 44(4):725-7. PubMed ID: 27096315 [TBL] [Abstract][Full Text] [Related]
32. CD4 Her Z; Tan JHL; Lim YS; Tan SY; Chan XY; Tan WWS; Liu M; Yong KSM; Lai F; Ceccarello E; Zheng Z; Fan Y; Chang KTE; Sun L; Chang SC; Chin CL; Lee GH; Dan YY; Chan YS; Lim SG; Chan JKY; Chandy KG; Chen Q Front Immunol; 2020; 11():580968. PubMed ID: 33013934 [TBL] [Abstract][Full Text] [Related]
33. Mesenteric lymph node CD4 Su L; Wu Z; Chi Y; Song Y; Xu J; Tan J; Cong X; Liu Y Cell Immunol; 2019 Mar; 337():33-41. PubMed ID: 30770094 [TBL] [Abstract][Full Text] [Related]
34. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321 [TBL] [Abstract][Full Text] [Related]
35. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease. Chen S; Guo H; Xie M; Zhou C; Zheng M Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577 [TBL] [Abstract][Full Text] [Related]
36. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. Yoo W; Gjuka D; Stevenson HL; Song X; Shen H; Yoo SY; Wang J; Fallon M; Ioannou GN; Harrison SA; Beretta L PLoS One; 2017; 12(12):e0189965. PubMed ID: 29244873 [TBL] [Abstract][Full Text] [Related]
37. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice. Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996 [TBL] [Abstract][Full Text] [Related]
38. Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease. Cairoli V; De Matteo E; Rios D; Lezama C; Galoppo M; Casciato P; Mullen E; Giadans C; Bertot G; Preciado MV; Valva P Sci Rep; 2021 Mar; 11(1):5129. PubMed ID: 33664397 [TBL] [Abstract][Full Text] [Related]
39. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J Front Immunol; 2020; 11():609900. PubMed ID: 33574818 [TBL] [Abstract][Full Text] [Related]